Allspring Global Investments Holdings LLC reduced its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 12.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 342,493 shares of the medical instruments supplier's stock after selling 48,126 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.62% of Glaukos worth $51,266,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently made changes to their positions in GKOS. WCM Investment Management LLC lifted its stake in Glaukos by 45.7% in the third quarter. WCM Investment Management LLC now owns 99,155 shares of the medical instruments supplier's stock worth $12,721,000 after purchasing an additional 31,084 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Glaukos by 186.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier's stock valued at $1,788,000 after acquiring an additional 8,942 shares during the period. First Turn Management LLC bought a new position in Glaukos in the 3rd quarter valued at $12,520,000. Harbor Capital Advisors Inc. purchased a new stake in Glaukos in the fourth quarter worth $3,679,000. Finally, Victory Capital Management Inc. lifted its position in shares of Glaukos by 421.8% during the third quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier's stock worth $10,320,000 after purchasing an additional 64,031 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.
Glaukos Stock Up 4.6 %
Shares of Glaukos stock traded up $6.68 during trading on Monday, reaching $153.06. The company's stock had a trading volume of 747,257 shares, compared to its average volume of 495,754. Glaukos Co. has a 1-year low of $83.90 and a 1-year high of $163.71. The company has a 50-day simple moving average of $151.95 and a two-hundred day simple moving average of $138.62. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a market cap of $8.44 billion, a price-to-earnings ratio of -50.68 and a beta of 1.04.
Insiders Place Their Bets
In related news, COO Joseph E. Gilliam sold 3,328 shares of the firm's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the transaction, the chief operating officer now owns 102,169 shares in the company, valued at $15,310,024.65. This trade represents a 3.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total value of $288,020.00. Following the sale, the director now directly owns 32,336 shares of the company's stock, valued at approximately $4,656,707.36. This represents a 5.82 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,328 shares of company stock valued at $2,289,521. 6.40% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
GKOS has been the subject of several research analyst reports. StockNews.com raised shares of Glaukos from a "sell" rating to a "hold" rating in a research note on Monday, October 21st. BTIG Research increased their price target on Glaukos from $140.00 to $149.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Wells Fargo & Company upped their price objective on shares of Glaukos from $145.00 to $153.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 11th. Piper Sandler reissued an "overweight" rating and set a $180.00 target price (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Finally, Truist Financial upped their price target on shares of Glaukos from $152.00 to $185.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $151.08.
Read Our Latest Stock Report on GKOS
About Glaukos
(
Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
See Also
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
